<DOC>
	<DOCNO>NCT02508038</DOCNO>
	<brief_summary>This phase I trial study safety transplantation haploidentical donor peripheral blood stem cell graft deplete TCRαβ+ cell CD19+ cell conjunction immunomodulating drug , Zoledronate , give post-transplant period treat pediatric patient relapse refractory hematologic malignancy high risk solid tumor .</brief_summary>
	<brief_title>TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate</brief_title>
	<detailed_description>REDUCED-INTENSITY CONDITIONING REGIMEN : Patients receive anti-thymocyte globulin ( ATG ) intravenously ( IV ) day -12 -9 , fludarabine phosphate IV day -8 -5 , thiotepa IV twice daily ( BID ) day -4 , melphalan IV day -3 -2 . PERIPHERAL BLOOD STEM CELL TRANSPLANTATION : Patients undergo TCR-αβ+ CD19+ deplete haploidentical donor peripheral blood stem cell transplantation day 0 . ZOLEDRONATE ADMINISTRATION : Patients receive zoledronate IV transplant determine assigned treatment group ( Cohort ) . Patients Cohort A receive zoledronate . Follow-up assessment occur transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Availability eligible haploidentical donor Hematologic malignancy Patients hematologic malignancy must HLA identical sibling suitable unrelated donor OR time need find acceptable unrelated donor match would likely result disease progression patient may become ineligible type potentially curative transplant Relapsed primary therapyrefractory AML bone marrow blast &lt; 20 % Highrisk refractory relapse ALL patient transplantation deem indicated ( primary induction failure hypodiploidy , relapse occur &lt; 30 month diagnosis , relapse previous allogeneic hematopoietic stem cell transplant [ alloHSCT ] , relapse 2nd remission ) Relapsed Hodgkin lymphoma unable achieve 2nd remission Very Good Partial Response ( VGPR ) therefore ineligible receive autologous hematopoietic stem cell transplant ( autoHSCT ) Hodgkin lymphoma relapse autoHSCT Primary refractory relapse nonHodgkin lymphoma unable achieve 2nd remission VGPR therefore ineligible receive autoHSCT NonHodgkin lymphoma relapse autoHSCT Myelodysplastic Syndrome/Myeloproliferative Syndrome Solid Tumor Patients solid tumor must fail ineligible receive autoHSCT autoHSCT would offer &gt; 20 % chance cure Neuroblastoma high risk relapse refractory disease Soft tissue sarcoma ( Rhabdomyosarcoma , Ewing sarcoma , Primitive Neuroectodermal Tumor highrisk extracranial solid tumor ) Relapsed primary refractory metastatic 1st complete remission , highrisk feature ( i.e. , &lt; 20 % survival conventional therapy ) Osteosarcoma Failure achieve Complete Response ( CR ) follow initial therapy Relapsed pulmonary bone metastasis achieve CR surgery and/or chemotherapy Karnofsky ( patient &gt; 16 year ) Lansky ( patient 16 year old ) performance score ≥ 60 Life expectancy ≥ 3 month Patient must fully recover acute toxic effect prior chemotherapy , immunotherapy , radiotherapy prior enter study Study enrollment earlier 3 month precede HSCT Glomerular Filtration Rate ( GFR ) ≥ 60 ml/min/1.73m2 Total bilirubin &lt; 3 mg/dL ALT ( alanine aminotransferase , SCPT ) ≤ 5 x Upper LImit Normal ( ULN ) age Ejection fraction &gt; 40 % Multigated Acquisition Scan ( MUGA ) echocardiogram No evidence dyspnea rest No supplemental oxygen requirement If measure , carbon monoxide diffusion capacity ( DLCO ) &gt; 50 % No severe peripheral neuropathy , sign leukoencephalopathy active Central Nervous System ( CNS ) infection Patients seizure disorder may enrol seizure well control anticonvulsant therapy If reproductive potential , negative pregnancy test willing use effective birth control method Informed consent patient legal guardian ( patient minor ) Pregnant breastfeed HIV infection Heart failure uncontrolled cardiac rhythm disturbance Active infection Prior organ allograft Significant serious intercurrent illness unrelated cancer treatment cover exclusion criterion expect significantly increase risk HSCT Any mental physical condition , opinion PI ( PI designee ) , could interfere ability subject ( parent legal guardian available care subject ) understand adhere requirement study Enrollment clinical study screen Day 100 ( unless PI judge enrollment would interfere endpoint study )</criteria>
	<gender>All</gender>
	<minimum_age>7 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>alpha beta deplete</keyword>
	<keyword>alphabeta</keyword>
	<keyword>TCR alpha beta deplete</keyword>
	<keyword>alpha beta</keyword>
	<keyword>haploidentical</keyword>
	<keyword>Zoledronate</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Pediatric cancer</keyword>
	<keyword>alfa beta</keyword>
	<keyword>αβ T cell deplete HSCT</keyword>
	<keyword>alpha beta T cell B cell deplete HSCT</keyword>
	<keyword>haploidentical HSCT</keyword>
</DOC>